Education
About Us
Working with TipRanks
Follow Us
Elicio Therapeutics (ELTX)
NASDAQ:ELTX
ELTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.70 - $12.42
Previous CloseN/A
Volume37.28K
Average Volume (3M)108.61K
Market Cap
$173.19M
Enterprise Value$116.79M
Total Cash (Recent Filing)$22.09M
Total Debt (Recent Filing)$14.90M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 06, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding16,338,284
10 Day Avg. Volume224,226
30 Day Avg. Volume108,612
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue100.17
Enterprise Value/Gross Profit-439.07
Enterprise Value/Ebitda-2.22
Forecast
1Y Price Target
$12.50Price Target Upside20.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe IDMC recommended that the randomized Phase 2 trial in KRAS mutated pancreatic cancer continue to the final analysis without interruption.
Expert EndorsementElicio's differentiated approach in treating mutant-KRAS driven pancreatic cancer has been underscored by leading experts, enhancing the company's credibility in the field.
Financial OutlookElicio has approximately $22.1 million in cash and equivalents and expects the cash runway to last into the first quarter of 2026.
Market PotentialPotential successful commercialization of ELI-002 7P across multiple solid tumor types could yield peak revenues exceeding $550M in the U.S. alone by 2035.
Bears Say
Investor SentimentStock slightly pulled back as some investors expected early stoppage of the trial due to a low hazard ratio at this interim analysis.
Market ChallengesPancreatic cancer remains a challenging indication, which could influence the overall success rate of the treatment.
Elicio Therapeutics News
ELTX FAQ
What was Elicio Therapeutics’s price range in the past 12 months?
Elicio Therapeutics lowest stock price was $3.70 and its highest was $12.42 in the past 12 months.
What is Elicio Therapeutics’s market cap?
Elicio Therapeutics’s market cap is $173.19M.
When is Elicio Therapeutics’s upcoming earnings report date?
Elicio Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.
How were Elicio Therapeutics’s earnings last quarter?
Elicio Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.685 by $0.025.
Is Elicio Therapeutics overvalued?
According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued.
Does Elicio Therapeutics pay dividends?
Elicio Therapeutics does not currently pay dividends.
What is Elicio Therapeutics’s EPS estimate?
Elicio Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Elicio Therapeutics have?
Elicio Therapeutics has 16,338,284 shares outstanding.
What happened to Elicio Therapeutics’s price movement after its last earnings report?
Elicio Therapeutics reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.685. Following the earnings report the stock price went up 1.433%.
Which hedge fund is a major shareholder of Elicio Therapeutics?
Currently, no hedge funds are holding shares in ELTX
Elicio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (20.42% Upside)
$12.50 (20.42% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.5%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.20%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
87.48%
Trailing 12-Months
Company Description
Elicio Therapeutics
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
ELTX Stock 12 Month Forecast
Average Price Target
$12.50
▲(20.42% Upside)
Technical Analysis
Black Diamond Therapeutics
―
Surrozen
―
Jade Biosciences
―
Tenaya Therapeutics
―
Ventyx Biosciences
―
Ownership Overview
34.32% Insiders
2.36% Mutual Funds
4.96% Other Institutional Investors
55.89% Public Companies and
Individual Investors